Mann J, Pietzner M, Wittemans L, Rolfe E, Kerrison N, Imamura F et al.

15 October 2020


Several genetic discoveries robustly implicate five single-nucleotide variants in the progression of non-alcoholic fatty liver disease to non-alcoholic steatohepatitis and fibrosis (NASH-fibrosis), including a recently identified variant in MTARC1. To better understand these variants as potential therapeutic targets, researchers aimed to characterize their impact on metabolism using comprehensive metabolomics data from two population-based studies